NO20101701L - Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for forebygging av en spesiell ikke-kreft, hormonavhengig sykdom og/eller en kardiovaskulaer sykdom - Google Patents

Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for forebygging av en spesiell ikke-kreft, hormonavhengig sykdom og/eller en kardiovaskulaer sykdom

Info

Publication number
NO20101701L
NO20101701L NO20101701A NO20101701A NO20101701L NO 20101701 L NO20101701 L NO 20101701L NO 20101701 A NO20101701 A NO 20101701A NO 20101701 A NO20101701 A NO 20101701A NO 20101701 L NO20101701 L NO 20101701L
Authority
NO
Norway
Prior art keywords
hydroxymatairesinol
cancer
prevention
hormone
disease
Prior art date
Application number
NO20101701A
Other languages
English (en)
Other versions
NO332110B1 (no
Inventor
Christer Eckerman
Risto Santti
Markku Ahotupa
Lauri Kangas
Sari Makela
Niina Saarinen
Anni Warri
Original Assignee
Hormos Nutraceutical Oy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20101701L publication Critical patent/NO20101701L/no
Application filed by Hormos Nutraceutical Oy Ltd filed Critical Hormos Nutraceutical Oy Ltd
Publication of NO332110B1 publication Critical patent/NO332110B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Denne oppfinnelse angår fremgangsmåter for forebygging av kreftsykdommer, visse hormomavhengige ikkekreft-sykdommer og/eller kardiovaskulære sykdommer hos en person, basert på administrering av hydroksymatairesinol til personen. Oppfinnelsen angår også en fremgangsmåte for øking av nivået av enterolakton eller en annen metabolitt av hydroksymatairesinol i en persons serum, hvorved det forårsakes forebygging av kreft eller en viss hormonavhengig ikkekreft-sykdom hos en person, basert på administrering av hydroksymatairesinol til personen. Denne oppfinnelse angår dessuten farmasøytiske preparater, matvaretilsetningsstoffer og matvareprodukter. omfattende hydroksymatairesinol.
NO20101701A 1999-03-30 2010-12-06 Hydroksymatairesinol for forebygging av ikke-kreft, ostrogenavhengig sykdom NO332110B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/281,094 US6451849B1 (en) 1999-03-30 1999-03-30 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
PCT/FI2000/000181 WO2000059946A1 (en) 1999-03-30 2000-03-09 Hydroxymatairesinol in cancer prevention

Publications (2)

Publication Number Publication Date
NO20101701L true NO20101701L (no) 2001-09-25
NO332110B1 NO332110B1 (no) 2012-06-25

Family

ID=23075932

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20014639A NO330135B1 (no) 1999-03-30 2001-09-25 Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for anvendelse for forebygging av en kreftform og farmasoytisk preparat
NO20101067A NO331188B1 (no) 1999-03-30 2010-07-27 Anvendelse av et flytende eller fast materiale anriket med hydroksymatairesinol, matvareprodukt samt fremgangsmate for oking av stabiliteten av et matvareprodukt
NO20101701A NO332110B1 (no) 1999-03-30 2010-12-06 Hydroksymatairesinol for forebygging av ikke-kreft, ostrogenavhengig sykdom
NO20111291A NO332251B1 (no) 1999-03-30 2011-09-23 Hydroksymatairesinol for forebygging av en kardiovaskulaer sykdom

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20014639A NO330135B1 (no) 1999-03-30 2001-09-25 Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for anvendelse for forebygging av en kreftform og farmasoytisk preparat
NO20101067A NO331188B1 (no) 1999-03-30 2010-07-27 Anvendelse av et flytende eller fast materiale anriket med hydroksymatairesinol, matvareprodukt samt fremgangsmate for oking av stabiliteten av et matvareprodukt

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20111291A NO332251B1 (no) 1999-03-30 2011-09-23 Hydroksymatairesinol for forebygging av en kardiovaskulaer sykdom

Country Status (25)

Country Link
US (2) US6451849B1 (no)
EP (1) EP1165537B1 (no)
JP (2) JP4852685B2 (no)
KR (2) KR100741724B1 (no)
CN (1) CN1146553C (no)
AT (1) ATE231500T1 (no)
AU (1) AU767691B2 (no)
BG (1) BG65380B1 (no)
BR (1) BR0007187A (no)
CA (2) CA2650297C (no)
CZ (2) CZ302730B6 (no)
DE (1) DE60001271T2 (no)
DK (1) DK1165537T3 (no)
EE (1) EE200100507A (no)
ES (1) ES2189738T3 (no)
HK (1) HK1045992B (no)
HU (1) HUP0200530A3 (no)
MX (1) MXPA01009714A (no)
NO (4) NO330135B1 (no)
NZ (1) NZ512099A (no)
PL (1) PL199892B1 (no)
RU (1) RU2241453C2 (no)
SK (2) SK287001B6 (no)
WO (1) WO2000059946A1 (no)
ZA (1) ZA200104440B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271257B1 (en) * 2000-04-17 2001-08-07 Hormos Nutraceutical Oy Ltd. Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
AU2001235969A1 (en) * 2000-10-23 2002-05-06 Council Of Scientific And Industrial Research Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
WO2003016883A1 (en) * 2001-08-16 2003-02-27 Analiza, Inc. A method of measuring solubility
CA2466663A1 (en) * 2001-11-12 2003-05-22 Analiza, Inc. Characterization of molecules
FI111638B (fi) * 2001-11-23 2003-08-29 Hormos Nutraceutical Oy Ltd Menetelmä hydroksimatairesinolin tuottamiseksi puusta
US7008666B2 (en) * 2001-11-26 2006-03-07 Hormos Nutraceutical Oy Ltd. Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
US20030144216A1 (en) * 2002-01-25 2003-07-31 Mikko Unkila Method for prevention of diseases in coeliac patients
US7528166B2 (en) * 2002-02-05 2009-05-05 Hormos Medical Corporation Lignan derivatives
US7048960B2 (en) * 2002-03-22 2006-05-23 Glenn Roy Pizzey High lignan flaxseed product and product by process
FI20021184A (fi) 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignaanivalmisteita
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
FR2851919A1 (fr) * 2003-03-03 2004-09-10 Lmd Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications
US8099242B2 (en) * 2003-06-12 2012-01-17 Analiza, Inc. Systems and methods for characterization of molecules
FI116727B (sv) 2003-11-12 2006-02-15 Arbonova Ab Oy Ny användning för kvistnötsextrakt
US7976877B2 (en) 2003-11-12 2011-07-12 Oy Arbonova Ab Use of knotwood extracts
KR20060115383A (ko) * 2003-12-26 2006-11-08 노우코우다이 티엘오 가부시키가이샤 간암 예방 및 치료용 조성물
US7666913B2 (en) * 2004-02-03 2010-02-23 Kotosugi Inc. Method of treating or preventing osteoporosis using isotaxiresinol derived from Taxus yunnanensis
AU2005323934A1 (en) * 2005-01-10 2006-07-13 Hormos Medical Ltd The use of a lignan for the manufacture of a composition for preventing or alleviating of symptoms relating to estrogen deficiency
US7595078B2 (en) * 2005-03-15 2009-09-29 Glanbia Nutritionals Ireland Limited Methods of increasing flaxseed hull recovery and resultant flax products
EP1977254B1 (en) 2005-12-19 2012-02-08 Analiza, Inc. Methods involving data patterns such as spectral biomarkers
DE102006008772A1 (de) * 2006-02-22 2007-08-23 Beiersdorf Ag Hydroxymatairesinol gegen trockene Haut
DE102006019044A1 (de) * 2006-04-25 2007-10-31 Merck Patent Gmbh Antioxidantien
FI20106293A0 (fi) * 2010-12-06 2010-12-06 Emilia Peuhu Uudet farmaseuttiset koostumukset
EP2517574B1 (de) 2011-04-29 2015-11-11 Symrise AG Bestimmte Vanillyllignane und deren Verwendung als Geschmacksverbesserer
WO2014025961A1 (en) 2012-08-10 2014-02-13 Analiza, Inc. Methods and devices for analyzing species to determine diseases
RU2510268C1 (ru) * 2012-11-14 2014-03-27 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс" Средство для лечения эстрогензависимых опухолей
JP2017515830A (ja) 2014-05-15 2017-06-15 リニア ソシエテ アノニム ７−ヒドロキシマタイレシノールを含む組成物
US9678076B2 (en) 2014-06-24 2017-06-13 Analiza, Inc. Methods and devices for determining a disease state
CZ305794B6 (cs) * 2015-04-20 2016-03-16 Výzkumný ústav potravinářský Praha, v.v.i. Způsob úpravy dřevních suků s přesně regulovanou strukturou drtě pro výrobu lignanů a zařízení k provádění tohoto způsobu, s využitím v potravinářské výrobě
US9669006B2 (en) 2015-07-28 2017-06-06 U.S. Nutraceuticals, LLC Composition and method to treat and alleviate symptoms of hot flashes in a female subject
CN108601803A (zh) * 2015-12-09 2018-09-28 格莱努拉有限公司 组合物用于降低哺乳动物的胆固醇水平的用途，其制备方法，组合物和用于制备包含所述组合物的食品添加剂的方法
IT201700050994A1 (it) * 2017-05-11 2018-11-11 Linnea Sa Uso di una Composizione comprendente 7-Idrossimatairesinolo
AU2022377268A1 (en) 2021-10-28 2024-05-23 Cleveland Diagnostics, Inc Partitioning systems and methods for determining multiple types of cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628228D0 (en) * 1986-11-26 1986-12-31 Inst Biolog Morya Dalnevostoch Composition inhibiting pathological addiction to alcohol
US4808674A (en) * 1987-08-24 1989-02-28 General Electric Company Aryl ester-grafted polyphenylene ethers and phenylene ether-amide graft copolymers prepared therefrom
DE4317466A1 (de) 1993-05-26 1994-12-01 Degussa Verbessertes Verfahren zur Bleiche von Holzstoffen
JPH10511699A (ja) 1995-10-18 1998-11-10 カノルト アルツナイミッテル ゲー エム ベー ハー リグナン及びその製造方法並びに医薬組成物及びその使用方法
WO1997032593A2 (en) 1996-03-08 1997-09-12 Energiser Plc Composition containing iso-flavonoids and lignans
US5846944A (en) 1996-04-04 1998-12-08 The University Of Saskatchewan Purified SDG as an antioxidant
JP2987365B1 (ja) * 1998-10-29 1999-12-06 かどや製油株式会社 抗酸化剤
KR20060115383A (ko) * 2003-12-26 2006-11-08 노우코우다이 티엘오 가부시키가이샤 간암 예방 및 치료용 조성물

Also Published As

Publication number Publication date
NO331188B1 (no) 2011-10-31
NO20014639D0 (no) 2001-09-25
PL350367A1 (en) 2002-12-02
JP4852685B2 (ja) 2012-01-11
CA2371839C (en) 2011-10-04
BG105856A (en) 2002-04-30
NZ512099A (en) 2004-01-30
CZ301725B6 (cs) 2010-06-02
KR20070027770A (ko) 2007-03-09
EE200100507A (et) 2002-12-16
DE60001271D1 (de) 2003-02-27
NO330135B1 (no) 2011-02-21
US6451849B1 (en) 2002-09-17
KR20010108434A (ko) 2001-12-07
BG65380B1 (bg) 2008-05-30
SK13262001A3 (sk) 2002-02-05
JP2002541158A (ja) 2002-12-03
SK287749B6 (sk) 2011-08-04
KR100741724B1 (ko) 2007-07-23
HK1045992B (zh) 2005-02-25
BR0007187A (pt) 2002-02-19
PL199892B1 (pl) 2008-11-28
NO332251B1 (no) 2012-08-06
ATE231500T1 (de) 2003-02-15
CZ302730B6 (cs) 2011-10-05
SK287001B6 (sk) 2009-09-07
AU767691B2 (en) 2003-11-20
US20010016590A1 (en) 2001-08-23
HUP0200530A3 (en) 2002-10-28
CN1146553C (zh) 2004-04-21
EP1165537A1 (en) 2002-01-02
EP1165537B1 (en) 2003-01-22
DE60001271T2 (de) 2003-07-31
CA2650297C (en) 2012-05-15
JP2011052024A (ja) 2011-03-17
NO20014639L (no) 2001-09-25
KR100741723B1 (ko) 2007-07-23
MXPA01009714A (es) 2003-06-24
CA2371839A1 (en) 2000-10-12
HK1045992A1 (en) 2002-12-20
WO2000059946A8 (en) 2001-01-25
NO332110B1 (no) 2012-06-25
CZ20013486A3 (cs) 2002-02-13
DK1165537T3 (da) 2003-05-12
RU2241453C2 (ru) 2004-12-10
NO20111291L (no) 2001-09-25
WO2000059946A1 (en) 2000-10-12
CA2650297A1 (en) 2000-10-12
AU3169200A (en) 2000-10-23
HUP0200530A2 (hu) 2002-07-29
NO20101067L (no) 2001-09-25
ZA200104440B (en) 2002-07-30
CN1345315A (zh) 2002-04-17
ES2189738T3 (es) 2003-07-16

Similar Documents

Publication Publication Date Title
NO20101701L (no) Hydroksymatairesinol eller en geometrisk isomer eller en stereoisomer derav for forebygging av en spesiell ikke-kreft, hormonavhengig sykdom og/eller en kardiovaskulaer sykdom
Neunteufl et al. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
MA27285A1 (fr) COMBINAISON D'AZELASTINE ET DE STEROiDES
WO2002051390A3 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
WO2001078680A3 (en) Pharmaceutical compositions comprising fluvastatin
WO2003013430A3 (en) Benzoquinone ansamycins
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
Lee et al. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6
EE9900162A (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation
HUP0101354A2 (hu) E-2-[4-(4-klór-1,2-difenil-1-butenil)-fenoxi]-etanol észterei, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
WO2003093503A3 (en) Method for bioequivalence determination using expression profiling
CY1107227T1 (el) Θεραπεια αυτοανοσων νοσων με εκχυλισμα αμερικανικου γκινσενγκ
IT8720438A0 (it) Esteri di 1,4:3,6-dianidrosorbitolo-2-mononitrato e 5-mononitrato, loro procedimento di preparazione e loro composizioni farmaceutiche.
Breijo-Márquez Misuse of the Drug Acenocoumarol in a Population of 250 Inhabitants with Non-valvular Atrial Fibrillation Assessed in a Region of Southeaster of Spain
BR9714945A (pt) Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos
CO5580753A2 (es) Composicion farmaceutica que comprende un antagonista ltb4 y un inhibidor cox-2 o un inhibidor cox1/2
Hodis et al. In perspective: estrogen therapy proves to safely and effectively reduce total mortality and coronary heart disease in recently postmenopausal women
WO2003041645A3 (en) Method of vaccinating a human patient to prevent metastatic tumors
WO2001039725A3 (en) Drug preparations
RU97113248A (ru) Усовершенствованная лекарственная форма человеческого интерферона-свеча
Ahokoski et al. Hormonal effects of MPV-2213ad, a novel, competitive aromatase inhibitor in healthy male volunteers. A phase I study
WO2002041871A3 (en) Composition comprising an imexon or derivatives thereof and lipids
IT1277118B1 (it) Composizioni farmaceutiche per il trattamento delle epatopatie croniche

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees